DOCSLIB.ORG

GSK Annual Report 2019 01 Our Business Model Continued

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Annual Report 2019 Contents We are a science-led Strategic report Our business model 01 global healthcare company Chairman’s statement 03 CEO’s statement 04 Financial performance 06 Our long-term priorities 09 Our purpose Our culture 10 To improve the quality of human life by helping people do more, feel better, Key performance indicators 11 live longer. Industry trends 12 Stakeholder engagement 15 Our goal Pharmaceuticals 17 To become one of the world’s most innovative, best-performing and trusted Vaccines 23 healthcare companies. Consumer Healthcare 27 Trust 30 Our strategy Risk management 43 To bring differentiated, high-quality and needed healthcare products Group financial review 49 to as many people as possible, with our three global businesses, scientific Corporate Governance and technical know-how and talented people. Chairman’s Governance statement 76 Our long-term priorities Our Board 78 Our Corporate Executive Team 82 Our priorities are underpinned by our ambition to build a more performance- Responsible leadership 84 focused culture, aligned to our values and expectations. Division of responsibilities 90 Innovation Composition, succession We invest in scientific and technical excellence to develop and launch and evaluation 92 a pipeline of new products that meet the needs of patients, payers Nominations Committee report 92 and consumers. Audit, risk and internal control 96 Audit & Risk Committee report 96 Performance Science Committee report 107 We deliver growth-based performance by investing effectively in our Corporate Responsibility business, developing our people and executing competitively. Committee report 109 Trust Section 172 statement 111 We are a responsible company and commit to use our science and Directors' report 113 technology to address health needs, make our products affordable Remuneration report and available and to be a modern employer. Chairman’s annual statement 116 Our values and expectations Annual report on remuneration 119 Our values – patient focus, transparency, respect and integrity. 2020 Remuneration policy summary 140 2020 Remuneration policy report 141 Our expectations – courage, accountability, development and teamwork. Financial statements Directors’ statement of responsibilities 152 Independent Auditor’s report 154 Financial statements 166 Notes to the financial statements 170 Financial statements of GlaxoSmithKline plc prepared under UK GAAP 252 Investor information Cautionary statement Quarterly trend 258 See the inside back cover of this document for the cautionary statement regarding Five-year record 263 forward-looking statements. Product development pipeline 269 Products, competition and Non-IFRS measures intellectual property 272 We use a number of adjusted, non-IFRS, measures to report the performance of our business. Principal risks and uncertainties 275 Total reported results represent the Group's overall performance under IFRS. Adjusted results, Share capital and share price 288 pro-forma growth rates and other non-IFRS measures may be considered in addition to, but not as a substitute for or superior to, information presented in accordance with IFRS. Adjusted results Dividends 290 and other non-IFRS measures are defined on pages 50 to 52 and reconciliations to the nearest Financial calendar 291 IFRS measures are on pages 62 and 65. Annual General Meeting 2020 291 We believe that Adjusted results, when considered together with Total results, provide investors, Tax information for shareholders 292 analysts and other stakeholders with helpful complementary information to understand better Shareholder services and contacts 294 the financial performance and position of the Group from period to period, and allow the Group's US law and regulation 296 performance to be more easily compared against the majority of its peer companies. These Group companies 299 measures are also used by management for planning and reporting purposes. They may not Glossary of terms 311 be directly comparable with similarly described measures used by other companies. Strategic report Governance and remuneration Financial statements Investor information Our business model We have three global businesses that discover, develop and manufacture innovative medicines, vaccines and consumer healthcare products. Every day, we help improve the health of millions of people around the world. Our operations span the value chain from identifying, Our ability to launch new products successfully and researching, developing and testing ground-breaking grow sales from our existing portfolio is key to our discoveries, to regulatory approval, manufacturing and commercial success. For patients and consumers commercialisation. we deliver transformational medicines, vaccines and We have over 99,000 employees across 95 countries consumer healthcare products. In 2019 that included with outstanding scientific and technical know-how and 2.3 billion packs of medicines, 701 million vaccine deep expertise in regulation, intellectual property and doses and 4.2 billion consumer healthcare products. commercialisation. We also work with world-leading As part of our capital allocation framework we invest experts and form strategic partnerships to complement in our three businesses and provide returns to our existing capabilities. shareholders in the form of dividends and share value Innovation is critical to how we improve health and create growth. In 2019 we paid a dividend of 80p per share financial value. As a research-based healthcare company and delivered £5.1 billion of free cash flow. we rely on intellectual property protection to help ensure We make a positive contribution to the communities a reasonable return on our investments so we can in which we operate by creating employment, working continue to research and develop new and innovative with suppliers and paying tax. We offer a broad range medicines. In 2019 we invested £4.6 billion in R&D. of employee benefits, including preventative healthcare In Pharmaceuticals and Vaccines we focus on science services, so that we are able to attract and retain the related to the immune system, human genetics and best people. By delivering on our purpose, the greatest advanced technology. In Consumer Healthcare we contribution we make is to improve the health of people leverage our scientific expertise and deep consumer around the world with our medicines, vaccines and insights to create healthcare products that meet consumer healthcare products. consumer demands. Pharmaceuticals Vaccines Consumer Healthcare Our Pharmaceuticals business has We are the world’s largest vaccines Our world-leading Consumer Healthcare a broad portfolio of innovative and company by revenue, delivering vaccines business combines science and established medicines in respiratory, that protect people at all stages of life. consumer insights to create innovative HIV, immuno-inflammation and oncology. Our R&D focuses on developing everyday healthcare brands that We are strengthening our R&D pipeline vaccines against infectious diseases consumers trust and experts recommend. through a focus on immunology, human that combine high medical need and In 2019, we finalised an agreement with genetics and advanced technologies strong market potential. Pfizer to combine our two consumer to help us identify transformational healthcare businesses. new medicines for patients. Read more on page 17 Read more on page 23 Read more on page 27 Turnover £m Turnover £m Turnover £m Respiratory 3,081 HIV 4,854 Meningitis 1,018 Wellness 4,526 Immuno-inflammation 613 Shingles 1,810 Oral health 2,673 Oncology 230 Influenza 541 Nutrition 1,176 Established Pharmaceuticals 8,776 Established Vaccines 3,788 Skin health 620 Total 17,554 Total 7, 157 Total 8,995 GSK Annual Report 2019 01 Our business model continued Preparing for the future Investing in R&D and new products The new programme will use the unique catalyst of separation In order to be successful, we are increasing investment in R&D to reset the capabilities and cost base for both companies, and new products to deliver future growth. Since announcing and help support delivery of the significant value creation our new approach to R&D in 2018, we have made significant opportunities we see in both New GSK and new Consumer progress to strengthen our pipeline, particularly in oncology. Healthcare. We now have 39 medicines and 15 vaccines in the pipeline, For New GSK, we see a clear opportunity to drive a common and in 2019 we had three major approvals, eight regulatory approach to R&D as science related to the immune system submissions, six positive read-outs from pivotal studies and converges across both pharmaceuticals and vaccines. This we progressed four new assets into pivotal studies. will enable us to be even more effective in how we allocate During 2019 we also completed transactions with Tesaro our budget, share technical and scientific expertise and deliver and with Merck KGaA, further strengthening our position our pipeline, regardless of modality. in oncology, and initiated alliances to build out our platform Under the programme, we will also seek to improve our technologies, in genomics with the University of California, capabilities and create efficiencies in our global support and in cell therapy with Lyell Immunopharma. functions; continue to simplify and focus our manufacturing The positive clinical data we are generating and the progress network, ensuring our supply chain is ready to launch our we have made to strengthen the pipeline underpins our decision new
Recommended publications
  • Darlene K. Susa-Anderson UL

    Darlene K. Susa-Anderson UL

    Fall Meeting Arlington, Virginia September 24-25, 2019 GHS in Asia Darlene K. Susa-Anderson UL Presenter biography Darlene Susa-Anderson is Senior Manager, Regulatory Affairs at UL (Underwriters Laboratories). She received her MS degree in Pharmacology-Toxicology from Duquesne University and her MS degree in Information Science from the University of Pittsburgh. Darlene received her BA degree from Carlow College in Pittsburgh, where she graduated Summa cum Laude with a double major in Biology and Mathematics. Darlene's 38+ years of experience include employment at the former Gulf Oil Corporation, Koppers Company, Calgon Corporation, and Fisher Scientific. Darlene's immediate past position prior to employment at ChemADVISOR was Director of Regulatory Affairs and Quality Assurance at Fisher Scientific. Ms. Susa-Anderson co-chaired the Chemical Manufacturers Association (now known as the American Chemistry Council) Labeling Work Group to revise the ANSI Standard for Industrial Chemicals - Industrial Labeling (ANSI Z129.1-1999) and was a member of the work group that revised the 1994 edition of this same standard. She also was a member of the work group that revised the ANSI Standard for Industrial Chemicals - MSDS Preparation (ANSI Z400.1-1998). Ms. Susa-Anderson served as Program Co-Chair for the Society for Chemical Hazard Communication (SCHC) for five years. She completed two terms on its Board of Directors (serving as Chairperson of the SCHC Board for the 2011-12 term) and additionally served as Vice President, President and Past President. Presentation abstract This presentation will provide an overview of GHS implementation status in the Asia Pacific region for 12 countries.
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C

    UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* GENOCEA BIOSCIENCES, INC. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 372427 10 4 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) July 30, 2015 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
  • Corporate Governance

    Corporate Governance

    Strategic report Governance and remuneration Financial statements Investor information Corporate Governance In this section Chairman’s Governance statement 78 The Board 80 Corporate Executive Team 83 Board architecture 85 Board roles and responsibilities 86 Board activity and principal decisions 87 Our purpose, values and culture 90 The Board’s approach to engagement 91 Board performance 94 Board Committee information 96 Our Board Committee reports 97 Section 172 statement 108 Directors’ report 109 GSK Annual Report 2020 77 Chairman’s Governance statement In last year’s Governance statement, I explained that our primary Education and focus on Science objective for 2020 was to ensure there was clarity between the Given the critical importance of strengthening the pipeline, Board and management on GSK’s execution of strategy and its the Board has benefitted from devoting a higher proportion of operational priorities. We have aligned our long-term priorities its time in understanding the science behind our strategy and of Innovation, Performance and Trust powered by culture testing its application. It is important that the Board has a and agreed on the metrics to measure delivery against them. working understanding of the key strategic themes upon The Board’s annual cycle of meetings ensures that all major which our R&D strategy is based. These themes have been components of our strategy are reviewed over the course complemented by Board R&D science thematic deep dives. of the year. Our focus was on the fundamentals of our strategy: human The COVID-19 pandemic impacted and dominated all our genetics, the immune system and AI and ML, as well as to lives for the majority of 2020.
  • Governance and Remuneration 2014

    Governance and Remuneration 2014

    Governance & remuneration reportStrategic In this section Our Board 72 Our Corporate Executive Team 76 Chairman’s letter 78 Corporate governance framework 79 Board report to shareholders Oversight and stewardship in 2014 and future actions 80 remuneration & Governance Leadership and effectiveness 82 Committee reports Audit & Risk 86 Nominations 92 Corporate Responsibility 94 Remuneration report Chairman’s annual statement 96 Annual report on remuneration 97 2014 Remuneration policy report 119 Financial statements Financial Investor information Investor GSK Annual Report 2014 71 Our Board Strategic reportStrategic Diversity Experience International experience Composition Tenure (Non-Executives) % % % % Scientific 19 Global 75 Executive 19 Up to 3 years 39 % % % % Finance 31 USA 100 Non-Executive 81 3-6 years 15 % % % % Industry 50 Europe 94 Male 69 7-9 years 23 % % % EMAP 63 Female 31 Over 9 years 23 Sir Christopher Gent 66 Skills and experience Chairman Sir Christopher has many years of experience of leading global businesses and a track record of delivering outstanding performance Governance & remuneration & Governance Nationality in highly competitive industries. He was appointed Managing Director British of Vodafone plc in 1985 and then became its Chief Executive Officer Appointment date in 1997 until his retirement in 2003. Sir Christopher was also a 1 June 2004 and as Chairman Non-Executive Director of Ferrari SpA and a member of the British on 1 January 2005 Airways International Business Advisory Board. Committee membership External appointments Corporate Responsibility Sir Christopher is a Senior Adviser at Bain & Co. Committee Chairman, Nominations, Remuneration and Finance Sir Philip Hampton 61 Skills and experience Chairman Designate Prior to joining GSK, Sir Philip chaired major FTSE 100 companies including J Sainsbury plc.
  • Annual Report and Accounts 2019

    Annual Report and Accounts 2019

    IMPERIAL BRANDS PLC BRANDS IMPERIAL ANNUAL REPORT AND ACCOUNTS 2019 ACCOUNTS AND REPORT ANNUAL ANNUAL REPORT AND ACCOUNTS 2019 OUR PURPOSE WE CAN I OWN Our purpose is to create something Everything See it, seize it, is possible, make it happen better for the world’s smokers with together we win our portfolio of high quality next generation and tobacco products. In doing so we are transforming WE SURPRISE I AM our business and strengthening New thinking, My contribution new actions, counts, think free, our sustainability and value creation. exceed what’s speak free, act possible with integrity OUR VALUES Our values express who we are and WE ENJOY I ENGAGE capture the behaviours we expect Thrive on Listen, challenge, share, make from everyone who works for us. make it fun connections The following table constitutes our Non-Financial Information Statement in compliance with Sections 414CA and 414CB of the Companies Act 2006. The information listed is incorporated by cross-reference. Additional Non-Financial Information is also available on our website www.imperialbrands.com. Policies and standards which Information necessary to understand our business Page Reporting requirement govern our approach1 and its impact, policy due diligence and outcomes reference Environmental matters • Occupational health, safety and Environmental targets 21 environmental policy and framework • Sustainable tobacco programme International management systems 21 Climate and energy 21 Reducing waste 19 Sustainable tobacco supply 20 Supporting wood sustainability
  • MORPHIC HOLDING, INC. (Name of Issuer)

    MORPHIC HOLDING, INC. (Name of Issuer)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) MORPHIC HOLDING, INC. (Name of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 61775R 10 5 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 23, 2020 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
  • PEDIARIX Is a Vaccine

    PEDIARIX Is a Vaccine

    HIGHLIGHTS OF PRESCRIBING INFORMATION • If Guillain-Barré syndrome occurs within 6 weeks of receipt of a prior These highlights do not include all the information needed to use vaccine containing tetanus toxoid, the decision to give PEDIARIX should PEDIARIX safely and effectively. See full prescribing information for be based on potential benefits and risks. (5.2) PEDIARIX. • The tip caps of the prefilled syringes contain natural rubber latex which may cause allergic reactions. (5.3) PEDIARIX [Diphtheria and Tetanus Toxoids and Acellular Pertussis • Syncope (fainting) can occur in association with administration of Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus injectable vaccines, including PEDIARIX. Procedures should be in place Vaccine], Suspension for Intramuscular Injection to avoid falling injury and to restore cerebral perfusion following Initial U.S. Approval: 2002 syncope. (5.4) • If temperature ≥105°F, collapse or shock-like state, or persistent, ----------------------------- INDICATIONS AND USAGE ---------------------------- PEDIARIX is a vaccine indicated for active immunization against diphtheria, inconsolable crying lasting ≥3 hours have occurred within 48 hours after tetanus, pertussis, infection caused by all known subtypes of hepatitis B virus, receipt of a pertussis-containing vaccine, or if seizures have occurred and poliomyelitis. PEDIARIX is approved for use as a 3-dose series in infants within 3 days after receipt of a pertussis-containing vaccine, the decision born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX to give PEDIARIX should be based on potential benefits and risks. (5.5) may be given as early as 6 weeks of age through 6 years of age (prior to the • For children at higher risk for seizures, an antipyretic may be 7th birthday).
  • To Arrive at the Total Scores, Each Company Is Marked out of 10 Across

    To Arrive at the Total Scores, Each Company Is Marked out of 10 Across

    BRITAIN’S MOST ADMIRED COMPANIES THE RESULTS 17th last year as it continues to do well in the growing LNG business, especially in Australia and Brazil. Veteran chief executive Frank Chapman is due to step down in the new year, and in October a row about overstated reserves hit the share price. Some pundits To arrive at the total scores, each company is reckon BG could become a take over target as a result. The biggest climber in the top 10 this year is marked out of 10 across nine criteria, such as quality Petrofac, up to fifth from 68th last year. The oilfield of management, value as a long-term investment, services group may not be as well known as some, but it is doing great business all the same. Its boss, Syrian- financial soundness and capacity to innovate. Here born Ayman Asfari, is one of the growing band of are the top 10 firms by these individual measures wealthy foreign entrepreneurs who choose to make London their operating base and home, to the benefit of both the Exchequer and the employment figures. In fourth place is Rolls-Royce, one of BMAC’s most Financial value as a long-term community and environmental soundness investment responsibility consistent high performers. Hardly a year goes past that it does not feature in the upper reaches of our table, 1= Rightmove 9.00 1 Diageo 8.61 1 Co-operative Bank 8.00 and it has topped its sector – aero and defence engi- 1= Rotork 9.00 2 Berkeley Group 8.40 2 BASF (UK & Ireland) 7.61 neering – for a decade.
  • British American Tobacco's Submission to the WHO's

    British American Tobacco's Submission to the WHO's

    British American Tobacco’s submission to the WHO’s Framework Convention on Tobacco Control This is the submission of the British American Tobacco group of companies commenting on the WHO’s Framework Convention on Tobacco Control. We are the world’s most international tobacco group with an active presence in 180 countries. Our companies sell some of the world’s best known brands including Dunhill, Kent, State Express 555, Lucky Strike, Benson & Hedges, Rothmans and Pall Mall. Executive summary • The WHO’s proposed ‘Framework Convention on Tobacco Control’ is fundamentally flawed and will not achieve its objectives. • The tobacco industry, along with other industries involved in the manufacture and distribution of legal but risky products, is the subject of considerable public attention. It is important that the debate about tobacco remains open, objective, constructive and free from opportunistic criticism if we are effectively to address the real issues associated with tobacco. • British American Tobacco is responsible tobacco. We seek to operate in partnership with governments, who are significant stakeholders in our business, and other interested parties, based on our open acknowledgement that we make a risky product and therefore support sensible regulation. • British American Tobacco shares the World Health Organisation’s desire to reduce the health impact of tobacco use. This paper outlines British American Tobacco’s proposal for the sensible regulation of tobacco. • Our proposal will relieve the WHO of the cost and bureaucracy involved in its wish to become a single global tobacco regulator, leaving it free to do what it should be doing – policy orientation. Some facts about tobacco • Today over one billion adults, about one third of the world’s adult population, choose to smoke.
  • Area Companies Offering Matching Gifts Below Is a Partial List of Area Companies Offering Matching Gifts

    Area Companies Offering Matching Gifts Below Is a Partial List of Area Companies Offering Matching Gifts

    Area Companies Offering Matching Gifts Below is a partial list of area companies offering matching gifts. Please check to see if your employer is on the list and/or check with your company if they offer the program. If your employer offers a matching gift program, please request a matching gift form from your employer or fill out their online form. Matching gifts can be made to the Tredyffrin Township Libraries, Paoli Library or Tredyffrin Public Library. Aetna FMC Corporation PNC Financial Services AIG GATX PPG Industries Air Products and Chemicals, Inc. GE Foundation PQ Corporation Allstate Foundation GlaxoSmithKline Procter & Gamble Altria Group, Inc. Glenmede Prudential Financial American Express Company Hillman Company PVR Partners, L.P. American International Group, Inc. Houghton Mifflin Quaker Chemical Corporation AmeriGas Propane, Inc. IBM Corporation Quest Diagnostics AON J.P. Morgan Chase Ross Arkema Inc. John Hancock Saint-Gobain Corporation Automatic Data Processing Johnson & Johnson Sandmeyer Steel Company AXA Foundation, Inc. JP Morgan Chase SAP Matching Gift Program Axiom Data, Inc. Kaplan Inc. Schering-Plough Foundation Bank of America Kellogg Schroder Investment Management Bemis Company Foundation KPMG LLP Shell Oil Company Berwind Corporation Liberty Mutual State Farm Companies Foundation BlackRock Lincoln Financial Group Subaru of America Boeing Company May Department Stores Sun Life Financial BP McDonald's Sun Microsystems, Inc Bristol-Myers Squibb Company McKesson Foundation Sunoco, Inc. C. R. Bard, Inc. Merck & Co., Inc. Tenet Healthcare Foundation CertainTeed Merrill Lynch Texas Instruments Charles Schwab Merrill Lynch ACE INA Foundation Chevron Corporation Microsoft AXA Foundation Chubb Group of Insurance Companies Minerals Technologies Inc. Dow Chemical Company CIGNA Foundation Mobil Foundation Inc.
  • Companies Subject to Exclusion

    Companies Subject to Exclusion

    Opdateret 01-08-2021 Vellivs Ekslusionsliste Velliv ønsker ikke at investere i selskaber, som bryder med Vellivs ESG-kriterier fastlagt i politikken for ansvarlig investering og aktivt ejerskab og som ikke udviser forandringsvilje i forhold til deres håndtering af ESG-risici. Endelig ønsker Velliv ikke at investere i tobaksselselskaber, selskaber med aktivteter i kontroversielle våben eller selskaber, hvor mere end 5 pct. af omsætningen stammer fra udvinding af kul og oliesand. Selsakb Kommentar 22nd Century Group, Inc. Tobacco AECOM Contr.Weapons Aerojet Rocketdyne Holdings, Inc. Contr.Weapons Aerojet Rocketdyne, Inc. Contr.Weapons Aeroteh SA Contr.Weapons Airbus SE Contr.Weapons Al-Eqbal Co. for Investment Plc Tobacco ALLETE, Inc. Kul Alliance Holdings GP LP Coal Alliance Resource Operating Partners LP Coal Alliance Resource Partners LP Coal Alpha Metallurgical Resources, Inc Coal Alpha Natural Resources Inc Coal Altadis Emisiones Financieras SA Tobacco Altadis SA Tobacco AltaGas Ltd. Gas/ESG Altius Minerals Corporation Coal Altria Group, Inc. Tobacco Anglo American plc Kul Anglo Pacific Group plc Coal Arch Resources, Inc. Coal Arcis Resources Corp. Tobacco Aryt Industries Ltd. Contr.Weapons Asenovgrad Tabac AD Tobacco Ashtrom Group Ltd. Normviolation>human rights Athabasca Oil Corporation Oilsand Avco Corp. Contr.Weapons B.A.T. Capital Corp. Tobacco B.A.T. Finance BV Tobacco B.A.T. International Finance Plc Tobacco Babcock International Group plc Contr.Weapons BADECO ADRIA dd Tobacco BAE Systems (Finance) Ltd. Contr.Weapons BAE Systems plc Contr.Weapons Bat Brasil Tobacco Bathurst Resources Limited Coal Baytex Energy (LP) Ltd. Oilsand Baytex Energy Corp. Oilsand Bellatora, Inc. Tobacco BHP Group Limited Kul BHP Group Plc Kul BlackPearl Resources, Inc.
  • Final Attendee List

    Final Attendee List

    Jennifer Abnet GlaxoSmithKline I GlaxoSmithKline I Jane Arboleda APRN Guardant I Molly Benson Sanjiv Agarwala MD Puma Biotechnology I Cancer Expert Now I Joe Arminger AbbVie I Seth Berkowitz LCSW, Manmeet Ahluwalia MD, CCLS MBA Patricia Armstrong The Leukemia & Lymphoma Miami Cancer Institute I Novartis I Society V Steve Albers Kim Arnold APRN CPNP Barry Berman MD, MS Alexion V CPHON Florida Cancer Specialists I Servier Pharmaceuticals I Maritza Alencar DNP, Tizano Bernard MBA, APRN, BMTCN Sheila Arrington MSN, Cancer Care Centers of Miami Cancer Institute V APRN, NP-C, AOCN Brevard I Puma Biotechnology I Carmen Allen MSIT Ana Mari Bernardini Pharmavoxx V Shannon Ashmon Novartis Oncology I Eisai, Inc I Luly Almeida Bernard Berry MBA Incyte Corporation I Sarah Ashton MS AstraZeneca Pharmaceuticals Guardant Health I I Talat Almukhtar MD Orlando Health Cancer Melissa Austin Jason Bever Institute I Cancer Care Centers of Oncopeptides I Brevard I Beatrice Alvarado Roberts Amy Bignon MD Garland Avera Doyle Caris Life Sciences I University of Florida I Jazz Pharmaceuticals I Nadeem Bilani MD Tadeu Ambros MD Francie Babcock Cleveland Clinic I FCS I AMAG Pharmaceuticals/Covis I Angela Bilik RN BSN Douglas Anderson AstraZeneca I Incyte Corporation I Craig Bailey Astra Zeneca I Jamie Bilsky BS Blesson Andrews Genentech V Genentech I Kevin Barr Daiichi Sankyo I Rohit Bishnoi MD Ollie Annum PharmD University of Florida I BHMCR I Leonard Bennett PharmD EMD Serono I Brady Blackman Susmitha Apuri MD MorphoSys I Florida Cancer Specialists I Michael Bennett As of 4-22-21 Kimberly Blandon RN MSN Rick Breitenstein Memorial Cancer Institute I Apellis Pharmaceuticals I Denise Capo Karyopharm Therapeutics I Taryn Boiteau GlaxoSmithKline I Amanda Bridges Florida Society of Clinical Heidi Caravetta Tracy Bonds RN, BSN, Oncology I Exelixis, Inc.